18f 4-l-fluoroglutamine
Small moleculeexperimentalImaging agent
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2012 (NCT01697930)
Timeline
2010s
- Jan 1, 2012
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
- Imaging
- 18-fluorine
Oral
No
Parenteral
No
Topical
No
Also known as
- 18f 4-l-fluoroglutamine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05452889 | Early Phase 1 (Phase 1) | Jan 31, 2023 | Bayer, National Heart, Lung, and Blood Institute (NHLBI), University of Pittsburgh |
| NCT03863457 | Phase 1 | Apr 5, 2019 | University of Pennsylvania |
| NCT01697930 | Phase 1 | Sep 1, 2012 | Cornell University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 1 | 0 | 1 | 2023 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2012 |
| National Heart, Lung, and Blood Institute (NHLBI) | Government | 1 | 0 | 1 | 2023 |
| University of Pennsylvania | Academic/Hospital | 1 | 1 | 1 | 2019 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1